Reduced intensity allogeneic stem cell transplant for treatment of blastic plasmacytoid dendritic cell neoplasm

Anand Lokare,1 Emmanouil Nikolousis,2 Neil Phillips,3 Zbigniew Rudzki,4 Richard Lovell,2 Bhuvan Kishore,2 Don Milligan,2 Shankara Panesha,2
1Hematology Department, University Hospital Walsgrave, Coventry; 2Hematology Department, Heart of England Hospital NHS Trust, Birmingham; 3Hematology Department, University Hospital North Staffordshire, Stoke on Trent, 4Histopathology Department, Heart of England NHS Trust, Birmingham, UK

Abstract

Blastic plasmacytoid dendritic cell neoplasm is a rare, aggressive tumor characterized by skin and/or marrow infiltration by CD4+ CD56+ cells. Historically, the tumor was variably thought to arise from either monocytes, T cells or NK cells giving rise to terms such as CD4+/CD56+ acute monoblastic leukemia, primary cutaneous CD4+/CD56+ hematodermic tumor and blastic NK-cell lymphoma. Whilst considerable progress has been made in understanding the histogenesis, the best modality of treatment remains to be defined. We are therefore reporting this case which was successfully treated with a T-deplete allogeneic transplant and the patient is currently alive and in remission 4 years post transplant.

Introduction

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive tumor characterized by skin and/or marrow infiltration by CD4+ CD56+ cells. Historically, the tumor was variably thought to arise from either monocytes, T cells or NK cells giving rise to terms such as CD4+/CD56+ acute monoblastic leukemia, primary cutaneous CD4+/CD56+ hematodermic tumor and Blastic NK-cell lymphoma. It is now believed that these tumors arise from plasmablastic dendritic cells (also called type 2 dendritic cells, DC2) which have a major role to play in antiviral immunity.1 Whilst considerable progress has been made in understanding the histogenesis, the best modality of treatment remains to be defined. Prognosis remains poor with median survival of only a few months as the tumor exhibits a progressive course despite initial response to chemotherapy.

Case Report

We report a 62 year old retired postman with a Karnofsky score of 100, who presented in December 2008 with a 6 month history of a slowly growing, painless, discolored skin lesion on his upper back. Physical examination revealed a 4 cm nodular, raised bruise like lesion (Figure 1). There was no associated lymphadenopathy or hepatosplenomegaly. Initial investigations showed pancytopenia with a hemoglobin 12.1 g/dL, white cell count 1.7×10^9/L, platelets 96×10^9/L and neutrophils 0.5×10^9/L. Bone marrow was markedly hypercellular with a diffuse infiltrate of large atypical lymphoblastoid cells displaying prominent nuclear folding and scant eosinophilic cytoplasm (Figure 2). Immunophenotyping revealed a 73% clone of CD4+/CD56+ cells. Immunostaining of the bone marrow biopsy showed tumor cells to be positive for CD212, BDC2A, CD4, CD56, CD45, CD43, CD13, CD14, CD16, CD11c, CD163, perforin, granzyme B, and CD138. Ki-67 expression was seen in about 50% cells. In situ hybridization for Epstein-Barr virus encoded RNA (EBER) was negative. Based on these findings, a diagnosis of blastic plasmacytoid dendritic cell neoplasm was made.

The patient was treated with one course each of CODOX-M (cyclophosphamide, vincristine, doxorubicin and methotrexate) and IVAC (ifosfamide, etoposide and cytarabine) chemotherapy. He was in complete remission following this treatment with regression of the skin lesion and in remission 4 years post transplant.

Discussion

BPDCN is a disease of the elderly with 70% of the cases occurring in patients older than 50 years. 90% present with cutaneous bruise-like lesions or asymptomatic nodules/plaques. Associated nodal and splenic involvement is also well known. Peripheral blood and/or marrow involvement is seen in 60-90% patients with cytopenias being the commonest presentation.1,2 Marrow shows heavy infiltration with CD4+ CD56+ cells/kg and neutrophil engraftment (neut>0.5) occurred on D+14 while platelet engraftment occurred on D+20 (PLT>20 unsupported). He had grade II skin graft vs host disease (GVHD) prophylaxis. Stem cell dose was 6×10^6 CD34+ cells/kg and neutrophil engraftment (neut>0.5) occurred on D+14 while platelet engraftment occurred on D+20 (PLT>20 unsupported). He is currently well, alive and in remission 49 months from initial diagnosis (44 months post-transplant) with full donor chimerism in both whole blood and T cell compartments. Donor lymphocyte infusions were not administered at any stage post transplant.

Conflict of interests: the authors declare no potential conflict of interests.

Correspondence: Emmanouil Nikolousis, Department of Hematology, Birmingham Heartlands Hospital, Bordesley Green East, Birmingham B9 5SS, UK. Tel: +44.0121.427.0704 - Fax: +44.0121.765.7538. E-mail: manos.nikolousis@heartofengland.nhs.uk

Key words: blastic plasmacytoid dendritic neoplasm, reduced intensity allograft, T-deplete.

Contributions: the authors contributed equally.

Accepted for publication: 12 January 2014. Revised received: 1 December 2013. Revision received: 8 October 2013. Received for publication: 8 October 2013.

This work is licensed under a Creative Commons Attribution NonCommercial License (CC BY-NC 3.0). doi:10.4081/hr.2014.5119

CoCopyright A. Lokare et al., 2014
Licensee PAGEPress, Italy
Hematology Reports 2014; 6:5119
Hematology Reports 2014; volume 6:5119

[page 4]

[Hematology Reports 2014; 6:5119]
ic leukemia is based on pattern of involvement, immunophenotype, T cell receptor (TCR) gene rearrangements and positivity for EBV. Some cases of BPDCN have relapsed with an acute myelomonocytic leukemia type clinical picture and the exact relationship between these diseases is not known.

Characteristically the tumor exhibits a progressive course despite initial response to variety of chemotherapy schedules, with a median time to progression of nine to 11 months and median survival of 13 months.1 Feuillard et al. published the 1st large series of 23 patients with CD4+CD56+ malignancies treated with a variety of chemotherapy protocols. 86% patients achieved complete remission (CR) but most relapsed with a median time to relapse of 9 months. Three patients had an allogeneic transplant in 1st complete remission (CR), with one patient relapsing at 12 months. Patrella et al.2 and Reichard et al.3 published the 2 other big series with 30 and 10 cases respectively. In the first publication 75% of patients responded to radiotherapy and/or chemotherapy but 90% cases relapsed with median time to relapse being 11 months. Only 3 of the 30 patients were alive with median overall survival (OS) being 14 months. None of the patients had an allogeneic transplant.1 Reimer et al.4 evaluated 97 patients treated with either i) chemotherapy less intensive than CHOP, ii) CHOP and CHOP-like regimens, iii) regimens used for acute leukemia and iv) autologous stem cell transplantation. Of the 97 patients, six received an allogeneic stem cell transplant, four with TBI based conditioning. Only two of the six patients relapsed (with median OS of 38.5 months). In an age-adjusted evaluation, only allogeneic stem cell transplant in first CR showed significant superiority in terms of overall survival to all other treatments in patients <60 years. Piccin et al.5 reported a patient who was successfully treated for BPDCN with a complex karyotype on an AML based regimen followed by an allogeneic stem cell transplant. In the pediatric setting Sakashita et al.6 reported a child with BPDCN treated with acute lymphoblastic leukemia-type regimen with skin and leukemic involvement followed by allogeneic stem cell transplant with a myeloablative protocol. In their review of 33 cases of pediatric BPDCN, the over survival was significantly lower in the patients with skin manifestation than those without cutaneous involvement and those patients with poor prognosis seemed more likely to benefit from an allogeneic stem cell transplant in first remission which resembles the characteristics of our patients.

The first patient we could find in reported literature who had a non-myeloablative allogeneic stem cell transplant for BPDCN was reported by Amor et al.7 We believe the patient we have reported in this review is the 2nd case treated with a reduced intensity conditioning Alemtuzumab based T-deplete conditioned allogeneic transplant. In light of our experience, reduced intensity T-deplete allogeneic stem cell transplant could be considered if age, performance status or comorbidities does not allow the use of a TBI based protocol. It appears a promising alternative in older patients with BPDCN and needs to be explored in future studies to improve the outcome in this disease.

References


Case Report

Figure 1. Bruise-like lesion on left side of thoracic vertebrae.

Figure 2. Bone marrow trephine showing medium sized cells with polymorphic, angulated nuclei with moderately basophilic chromatin and scant cosinophilic cytoplasm. Morphologically these cells resemble atypical lymphocytes. Mitoses are numerous (H&E, 63×).


